TinyGemsBreaks Archive - Page 9 of 133

FridayJul 11, 2025 9:00 am

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in NetworkNewsWire Spotlight on Genetic Medicines

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company's initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options. To view the full press release, visit: https://ibn.fm/18sdm About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology…

ThursdayJul 10, 2025 2:44 pm

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Signs LOI to Launch David Lloyd-Branded U.S. Sports Arena

SEGG Media (NASDAQ: SEGG, LTRYW), a global technology company at the intersection of sports, entertainment and gaming, has signed a binding Letter of Intent with legendary sports entrepreneur David Lloyd to acquire the rights to his All-Sports Arena in Boca Raton, Florida, at a $14 million valuation. Signed during Wimbledon at the Members’ Enclosure, the agreement marks the U.S. debut of the David Lloyd brand. The 100,000-square-foot facility will be branded “Sports.com All-Sports Arena, designed by David Lloyd,” blending premium athletic infrastructure, co-working space, and hospitality elements. It will feature AI-powered golf simulators, indoor courts, a full-service gym, and a…

ThursdayJul 10, 2025 11:37 am

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds…

WednesdayJul 09, 2025 11:31 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers in the brain and central nervous system, announced CEO John Climaco’s participation in a Virtual Investor CEO Connect segment. Climaco provided an overview of the Company’s lead candidate, TPI 287, and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, Massachusetts. To view the full press release, visit https://ibn.fm/cRmQS About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The…

TuesdayJul 08, 2025 2:35 pm

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Emerges from Lottery.com Rebrand with Global Sports, Entertainment and Gaming Vision

SEGG Media (NASDAQ: SEGG, LTRYW), formerly Lottery.com Inc., has completed its corporate rebrand and strategic overhaul, signaling a new era as a global sports, entertainment, and ethical gaming conglomerate. Trading under the new SEGG ticker, the company now operates across three verticals: Sports.com (live streaming, sim racing, eSports), Entertainment (event streaming, music, fashion), and Lottery.com (iGaming and charity-aligned gaming). Following a $300 million equity line, SEGG Media is focused on non-dilutive growth, asset-backed acquisitions, and fan-first digital experiences, with major initiatives expected in global motorsports, storytelling content, and branded facilities. To view the full press release, visit https://ibn.fm/4RHJC About SEGG…

TuesdayJul 08, 2025 12:18 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer. To view the full press release, visit: https://ibn.fm/wj9TN About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed…

MondayJun 30, 2025 9:20 am

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Issues CEO Update, Reaffirms Commitment to Growth Following Leadership Transition

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the company’s future following the recent passing of CEO and Chairman Charles M. Fernandez. The letter highlights internal reviews, meetings with subsidiary leaders, and plans for increased focus, coordination, and strategic investment to build on the company’s existing foundation and drive long-term value creation. To view the full press release, visit: https://ibn.fm/1sOGY About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist…

FridayJun 27, 2025 10:20 am

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end…

TuesdayJun 24, 2025 3:28 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications. To view the full press release, visit https://ibn.fm/f2RrI About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of…

TuesdayJun 24, 2025 2:46 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks